An observational study in Transthyretin Amyloidosis, ATTR-CM and ATTRv-PN, sponsored by AstraZeneca. Recruiting at 89 sites in 6 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-09-23.
Sponsored by AstraZeneca · Observational
The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes. In addition, information on the effectiveness of ATTR amyloidosis treatments, including eplontersen, which is a ligand-conjugated antisense oligonucleotide gene silencing treatment targeting activity against both the mutant and wild-type TTR protein, will be collected.
MaesTTRo is an international, longitudinal, non-interventional study of adult patients with transthyretin (ATTR) amyloidosis.
The study plans to enroll a minimum of 1850 patients with ATTR amyloidosis, including a minimum of 850 patients with ATTR cardiomyopathy (ATTR-CM), and a minimum of 100 patients with ATTRv-PN hereditary polyneuropathy.
The enrollment period is expected to last approximately 4 years. The duration of follow-up for each patient will be at least 3 years and up to 7 years depending on the date when the patient is enrolled.
This study design will include both primary and secondary data. Primary data will consist of patient-reported outcome (PRO) questionnaires. Patients will be asked to complete electronic PRO questionnaires at enrollment and every 6 months (±3 months) only during routine visits. Secondary data will consist of demographic, clinical, and treatment information, and will be collected as per routine clinical practice. These data will be abstracted directly from the electronic health record or review of paper charts for each patient and entered in the electronic data capture system. No site visits are required for this study, and patients will not be contacted for data collection outside of routine clinic visits.
For patients enrolled in the United States, a tokenization process (creation of a unique, encrypted identifier called a token, in place of personal identifiable information) will be used to collect additional de-identified data (e.g., healthcare resource use, healthcare costs) from other sources that are part of patients' routine medical care (electronic medical, hospital, or pharmacy records). Only de-identified data will be analyzed. Patients will be given a choice within the informed consent form to opt in or opt out of participating in the tokenization process.
82 studies on the registry are indexed under Amyloidosis, Hereditary, Transthyretin-Related; 28 are open to participants now.
This study's planned enrollment of 1,850 is above the median of 100 across 40 observational studies indexed under Amyloidosis, Hereditary, Transthyretin-Related.
Browse Amyloidosis, Hereditary, Transthyretin-Related studies →AstraZeneca is the lead sponsor of 3,499 studies on the registry; 270 are open to participants now.
Of its 368 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients with a diagnosis of amyloid transthyretin (ATTR) amyloidosis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with ATTR-CM at enrollment
Drug: Treatment of transthyretin (ATTR) amyloidosis in observational study setting
Patients with ATTRv-PN at enrollment
Drug: Treatment of transthyretin (ATTR) amyloidosis in observational study setting
Patients with a mixed ATTR amyloidosis phenotype
Drug: Treatment of transthyretin (ATTR) amyloidosis in observational study setting
Data will be collected on patients with ATTR amyloidosis in a real-world setting
Demographic characteristics (overall and in patients initiating a treatment with eplontersen)
* Age * Sex as determined by the investigator (male/female) * Race and ethnicity, where allowed
Time frame: From time of enrollment for up to 7 years
Treatment patterns (overall and in patients initiating a treatment with eplontersen)
In order to address this objective, the following treatments will be assessed: * ATTR amyloidosis treatment: Tafamidis, Diflunisal, Acoramidis, Vutrisiran, Patisiran, Inotersen, Eplontersen, Doxycycline and taurodesoxycholic acid, Liver transplant * Heart failure/arrhythmia-related treatment: Diuretics, Angiotensin converting enzyme inhibitor, Angiotensin receptor blocker, Angiotensin receptor-neprilysin inhibitor, Anticoagulation, Beta-blockers, Sodium-glucose co-transporter-2 inhibitor, Mineralocorticoid receptor antagonist, Digoxin, Pacemaker use, Implantable cardioverter-defibrillator, Left ventricular assist device, Cardiac transplant, Transcatheter aortic valve replacement, Surgical aortic valve replacement * Polyneuropathy-related treatment: Antiepileptics (gabapentin, pregabalin, carbamazepine, phenytoin), Antidepressants, Topical pain treatments, Opioids, Tetrahydrocannabinol * Other: Medications for gastrointestinal symptoms, Vitamin A supplementation, Dialysis
Time frame: From time of enrollment for up to 7 years
Clinical characteristics (overall and in patients initiating a treatment with eplontersen)
In order to address this objective, the following clinical characteristics will be assessed: * Modified body mass index (mBMI) * Medical history * TTR genetic test results * Family history of ATTR * Time period between the first symptoms to date of diagnosis of ATTR * Time since diagnosis of ATTR
Time frame: From time of enrollment for up to 7 years
Findings from biopsy (overall and in patients initiating a treatment with eplontersen)
In order to address this objective, the following biopsy information will be collected: * Type of biopsy * Amyloid identification result (Positive, Negative, Inconclusive for amyloid) * Method of amyloid typing * Result of the biopsy (Normal/Abnormal) * Reason for considering the biopsy result abnormal
Time frame: From time of enrollment for up to 7 years
Findings from Cardiovascular magnetic resonance imaging (CMR) (overall and in patients initiating a treatment with eplontersen)
In order to address this objective, the following information will be collected: extracellular volume (ECV), contrast use, left ventricular (LV) end-diastolic volume, LV end-systolic volume, LV ejection fraction, LV Mass Index, interventricular wall thickness, right ventricular Free Wall Thickness, LV Free Wall Thickness, left Atrial Volume Index, native T1 mapping, CMR result (Normal/Abnormal), reason for considering the result abnormal.
Time frame: From time of enrollment for up to 7 years
Findings from Bone tracer cardiac scintigraphy (overall and in patients initiating a treatment with eplontersen)
In order to address this objective, the following information will be collected: Type of tracer, Heart to contralateral lung ratio (H/CL), Perugini grade, scintigraphy result (Normal/Abnormal), reason for considering the result abnormal.
Time frame: From time of enrollment for up to 7 years
Findings from Echocardiography (overall and in patients initiating a treatment with eplontersen)
In order to address this objective, the following information will be collected: LV ejection fraction, LV End Diastolic Volume, LV End Systolic Volume LV End Diastolic Dimension, LV End Systolic Dimension, Interventricular Septal Thickness End Diastole, Posterial Wall Thickness End Diastole, Left Ventricular Mass Index, Left Atrial Volume, Left Atrial Volume Index, Mitral valve regurgitation, Aortic valve regurgitation, Tricuspid valve regurgitation, Pulmonic valve regurgitation, LV Outflow Gradient, Stroke Volume, Lateral early diastolic myocardial velocity (e' lateral), Medial early diastolic myocardial velocity (e' medial), Mitral E/e' Ratio, Early diastolic mitral inflow velocity (E), Late diastolic mitral inflow velocity (A), Mitral Peak E/A Ratio, Global LV longitudinal strain, Pulmonary artery systolic pressure, RV Free Wall Thickness Severity of Aortic stenosis, Severity of Mitral stenosis.
Time frame: From time of enrollment for up to 7 years
ECG variables (overall and in patients initiating a treatment with eplontersen)
In order to address this objective, the following ECG information will be collected: * Interpretation of the ECG (Normal/Abnormal/Borderline) * Heart rhythm * Presence of extrasystoles * Presence of conduction abnormalities * Evidence of left ventricular hypertrophy (LVH)
Time frame: From time of enrollment for up to 7 years
Sural nerve and tibial nerve amplitude (overall and in patients initiating a treatment with eplontersen)
Sural nerve and tibial nerve amplitude will be measured in overall and in patients initiating a treatment with eplontersen
Time frame: From time of enrollment for up to 7 years
Biomarker results (overall and in patients initiating a treatment with eplontersen)
In order to address this objective, the following biomarker results will be collected: * Serum TTR levels * Complete blood count * Hemoglobin * Troponin I * Cystatin * Creatinine * Reported glomerular filtration rate (GFR) * Albumin * Liver enzymes: alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyl transferase (GGT), total bilirubin * N-terminal pro B-type natriuretic peptide (NT-proBNP) * Vitamin A level * Neurofilament light chain (NfL) * International normalized ratio (INR) test
Time frame: From time of enrollment for up to 7 years
Urine test results (overall and in patients initiating a treatment with eplontersen)
In order to address this objective, the following test results will be collected: * Urine albumin-creatinine ratio (UACR) * Urine protein creatinine ratio (UPCR)
Time frame: From time of enrollment for up to 7 years
Clinical manifestations (signs and symptoms) of ATTR amyloidosis (overall and in patients initiating a treatment with eplontersen)
In order to address this objective, the following clinical manifestations will be assessed: ischemic heart disease, acute myocardial infarction, heart failure, atrial fibrillation, arrhythmias, conduction system disease, aortic valve stenosis polyneuropathy, carpal tunnel syndrome, autonomic neuropathy, nephrotic syndrome, subnephrotic proteinuria, gastrointestinal dysfunction, chronic kidney disease / acute kidney injury, spinal stenosis, spinal stenosis surgery, hepatomegaly, ascites, oedema, other amyloidosis related manifestations (e.g., Popeye's sign, tendon rupture)
Time frame: From time of enrollment for up to 7 years
36-Item Short Form Health Survey Version 2 (SF-36v2) Physical Component Summary score (overall and in patients initiating a treatment with eplontersen)
The SF-36v2 is a 36-item, generic health survey that provides scores for eight health domains (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health) and two summary scores; the physical component summary (PCS) score and the mental component summary (MCS) score. Higher scores indicate a better health state.
Time frame: From time of enrollment for up to 7 years
Norfolk Quality of Life-Diabetic Neuropathy total score (overall and in patients initiating a treatment with eplontersen)
The Norfolk QOL-DN is a 35-item, disease-specific instrument that provides scores for five domains (symptoms, large fiber neuropathy, small fiber neuropathy, autonomic neuropathy, and activities of daily living) and a total score. Higher scores indicate a worse health state.
Time frame: From time of enrollment for up to 7 years
Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score (overall and in patients initiating a treatment with eplontersen)
The KCCQ is a 23-item, disease-specific questionnaire that assesses seven domains (physical limitations, symptom stability, symptom frequency, symptom burden, self-efficacy, quality of life, and social limitation) and provides three summary scores (total symptom score, clinical summary score, and overall summary score). Higher scores indicate a better health state.
Time frame: From time of enrollment for up to 7 years
New York Heart Association (NYHA) classification (overall and in patients initiating a treatment with eplontersen)
I=No symptoms; II=Symptoms with ordinary physical activity; III=Symptoms with less than ordinary physical activity; IV=Symptoms at rest.
Time frame: From time of enrollment for up to 7 years
National Amyloidosis Centre (NAC) ATTR staging or Mayo staging (overall and in patients initiating a treatment with eplontersen)
For NAC staging, Stage I: N-terminal pro-brain natriuretic peptide (NT-proBNP) ≤3000 ng/L and estimated glomerular filtration rate (eGFR) ≥45 ml/min; Stage III: NT-proBNP \>3000 ng/L and eGFR \<45 ml/min; Stage IV:NT-proBNP ≥10,000 ng/L; Stage II: remainder of patients For Mayo staging, Stage I: Both and biomarker values are below the established thresholds; Stage II: Either troponin T or NT-proBNP is above the threshold; Stage III: Both troponin T and NT-proBNP biomarker values are above the threshold. Biomarker Thresholds: Troponin T: \>0.05 mg/mL and NT-proBNP: \>3000 pg/mL.
Time frame: From time of enrollment for up to 7 years
Familial amyloid polyneuropathy (FAP) (Coutinho) staging (overall and in patients initiating a treatment with eplontersen)
Stage 0: No symptoms; Stage I: Unimpaired ambulation; mostly mild sensory, motor and autonomic neuropathy in the lower limbs; Stage II: Assistance with ambulation required, mostly moderate impairment progression to the lower limbs, upper limbs, and trunk; Stage III: Wheelchair-bound or bedridden; severe sensory, motor, and autonomic involvement of all limbs.
Time frame: From time of enrollment for up to 7 years
Polyneuropathy disability (PND) score (overall and in patients initiating a treatment with eplontersen)
Stage 0=No symptoms; Stage I=Sensory disturbances but preserved walking capabilities; Stage II=Impaired walking capacity, but ability to walk without a stick or crutches; Stage IIIA=Walking with help of 1 stick or crutch; Stage IIIB=Walking with the help of 2 sticks or crutches; Stage IV=confined to wheel chair or bedridden.
Time frame: From time of enrollment for up to 7 years
Left Ventricular Ejection Fraction (overall and in patients initiating a treatment with eplontersen)
Left Ventricular Ejection Fraction will be measured in overall and in patients initiating a treatment with eplontersen
Time frame: From time of enrollment for up to 7 years
6-minute walk test (overall and in patients initiating a treatment with eplontersen)
To address this objective, the distance walked in 6 minutes will be measured.
Time frame: From time of enrollment for up to 7 years
Charlson comorbidity index (CCI) and CCI components (overall and in patients initiating a treatment with eplontersen)
In order to address CCI, most recent score and all CCI componenet will be measured * Myocardial infarction * Congestive heart failure * Peripheral vascular disease * Cerebrovascular disease * Dementia * Chronic pulmonary disease * Rheumatic disease * Peptic ulcer disease * Diabetes (None, Without chronic complications, With chronic complications) * Hemiplegia or paraplegia * Renal disease * Any malignancy, including lymphoma and leukemia, except malignant neoplasm of skin (None, Localized, Metastatic) * Liver disease (None, Mild, Moderate, Severe) * Metastatic solid tumor * Acquired immune deficiency syndrome (AIDS) / Human immunodeficiency virus (HIV)
Time frame: From time of enrollment for up to 7 years
Other comorbidities of interest (overall and in patients initiating a treatment with eplontersen)
In order to address this objective, the following information will be collected: * Percentage of patients with depression * Percentage of patients with fibromyalgia * Percentage of patients with paraproteinemia
Time frame: From time of enrollment for up to 7 years
Healthcare resource utilization (overall and in patients initiating a treatment with eplontersen)
In order to address this objective, the following information will be collected: * Number of emergency department visits * Number of outpatient visits * Inpatient care/hospitalization general ward (non-intensive): number of inpatient stays, number of bed days * Inpatient care/hospitalization intensive ward: number of inpatient stays, number of bed days
Time frame: From time of enrollment for up to 7 years
Mortality (overall and in patients initiating a treatment with eplontersen)
Mortality during study follow-up (all-cause, related to ATTR amyloidosis), overall and by NYHA/NAC or Mayo/FAP stage
Time frame: Throughout study follow-up (up to 7 years)
Liver Disease and Live Transplant
* Liver disease (for patients with mild, moderate or severe liver disease: Child Pugh score, Child Pugh class, ascites, encephalopathy) * Liver transplantation (reason for transplant, type of transplant)
Time frame: From time of Enrollment for up to 7 Years
Comparison of demographic and clinical characteristics of patients prescribed eplontersen at any time during the observation period to patients on other ATTR treatments
The following outcomes will be compared between patients treated with eplontersen and patients on other ATTR treatments: * Demographics * mBMI * Medical history * Family history of ATTR amyloidosis * Time period between the first symptoms to date of diagnosis of ATTR amyloidosis * Time since diagnosis of ATTR amyloidosis
Time frame: Up to 7 years
Comparison of findings from biopsy in patients prescribed eplontersen at any time during the observation period to patients on other ATTR treatments
The following outcomes will be compared between patients treated with eplontersen and patients on other ATTR treatments: * Type of biopsy * Amyloid identification result (Positive, Negative, Inconclusive for amyloid) * Method of amyloid typing * Result of the biopsy (Normal/Abnormal) * Reason for considering the biopsy result abnormal
Time frame: Up to 7 years
Comparison of findings from Cardiovascular magnetic resonance imaging (CMR) in patients prescribed eplontersen at any time during the observation period to patients on other ATTR treatments
The following outcomes will be compared between patients treated with eplontersen and patients on other ATTR treatments: extracellular volume (ECV), contrast use, left ventricular (LV) end-diastolic volume, LV end-systolic volume, LV ejection fraction, LV Mass Index, interventricular wall thickness, right ventricular Free Wall Thickness, LV Free Wall Thickness, left Atrial Volume Index, native T1 mapping, CMR result (Normal/Abnormal), reason for considering the result abnormal.
Time frame: Up to 7 years
Comparison of findings from Echocardiography in patients prescribed eplontersen at any time during the observation period to patients on other ATTR treatments
The following outcomes will be compared between patients treated with eplontersen and patients on other ATTR treatments: LV ejection fraction, LV End Diastolic Volume, LV End Systolic Volume LV End Diastolic Dimension, LV End Systolic Dimension, Interventricular Septal, Thickness Diastole, Posterial Wall Thickness Diastole, Left Ventricular Mass Index, Left Atrial Volume, Left Atrial Volume Index, Mitral valve regurgitation, Aortic valve regurgitation, Tricuspid valve regurgitation, Pulmonic valve regurgitation, LV Outflow Gradient, Stroke Volume, Lateral early diastolic myocardial velocity (e' lateral), Medial early diastolic myocardial velocity (e' medial), Mitral E/e' Ratio, Early diastolic mitral inflow velocity (E), Late diastolic mitral inflow velocity (A), Mitral Peak E/A Ratio, Global LV longitudinal strain, Pulmonary artery systolic pressure, RV Free Wall Thickness Severity of Aortic stenosis, Severity of Mitral stenosis.
Time frame: Up to 7 years
Comparison of ECG variables of patients prescribed eplontersen at any time during the observation period to patients on other ATTR treatments
The following outcomes will be compared between patients treated with eplontersen and patients on other ATTR treatments: * Interpretation of the ECG (Normal/Abnormal/Borderline) * Heart rhythm * Presence of extrasystoles * Presence of conduction abnormalities * Evidence of left ventricular hypertrophy (LVH)
Time frame: Up to 7 years
Comparison of findings from Bone tracer cardiac scintigraphyin patients prescribed eplontersen at any time during the observation period to patients on other ATTR treatments
The following outcomes will be compared between patients treated with eplontersen and patients on other ATTR treatments: Type of tracer, Heart to contralateral lung ratio (H/CL), Perugini grade, scintigraphy result (Normal/Abnormal), reason for considering the result abnormal.
Time frame: Up to 7 years
Comparison of sural nerve and tibial nerve amplitude in patients prescribed eplontersen at any time during the observation eriod to patients on other ATTR treatments
Sural nerve and tibial nerve amplitude will be compared in patients prescribed eplontersen at any time during the observation period to patients on other ATTR treatments
Time frame: Up to 7 years
Comparison of biomarker results in patients prescribed eplontersen at any time during the observation eriod to patients on other ATTR treatments
The following outcomes will be compared between patients treated with eplontersen and patients on other ATTR treatments: * Serum TTR levels * Complete blood count * Hemoglobin * Troponin I * Cystatin * Creatinine * Reported glomerular filtration rate (GFR) * Albumin * Liver enzymes: alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyl transferase (GGT), total bilirubin * N-terminal pro B-type natriuretic peptide (NT-proBNP) * Vitamin A level * Neurofilament light chain (NfL) * International normalized ratio (INR) test
Time frame: Up to 7 years
Comparison of urine test results in patients prescribed eplontersen at any time during the observation eriod to patients on other ATTR treatments
The following outcomes will be compared between patients treated with eplontersen and patients on other ATTR treatments: * Urine albumin-creatinine ratio (UACR) * Urine protein creatinine ratio (UPCR)
Time frame: Up to 7 years
Comparison of Clinical manifestations (signs and symptoms) of ATTR amyloidosis in patients prescribed eplontersen to patients on other ATTR treatments
The following outcomes will be compared between patients treated with eplontersen and patients on other ATTR treatments: ischemic heart disease, acute myocardial infarction, heart failure, atrial fibrillation, arrhythmias, conduction system disease, aortic valve stenosis polyneuropathy, carpal tunnel syndrome, autonomic neuropathy, nephrotic syndrome, subnephrotic proteinuria, gastrointestinal dysfunction, chronic kidney disease / acute kidney injury, spinal stenosis, spinal stenosis surgery, hepatomegaly, ascites, oedema, other amyloidosis related manifestations (e.g., Popeye's sign, tendon rupture)
Time frame: Up to 7 years
Comparison of 36-Item Short Form Health Survey Version 2 (SF-36v2) Physical Component Summary score in patients prescribed eplontersen to patients on other ATTR treatments
SF-36v2, physical component summary scores will be compared between patients treated with eplontersen and patients on other ATTR treatments.
Time frame: Up to 7 years
Comparison of Norfolk Quality of Life-Diabetic Neuropathy total score in patients prescribed eplontersen to patients on other ATTR treatments
Norfolk Quality of Life-Diabetic Neuropathy total scores will be compared between patients treated with eplontersen and patients on other ATTR treatments.
Time frame: Up to 7 years
Comparison of Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score in patients prescribed eplontersen to patients on other ATTR treatments
Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score will be compared in patients prescribed eplontersen to patients on other ATTR treatments
Time frame: Up to 7 years
Comparison of New York Heart Association (NYHA) classification in patients prescribed eplontersen to patients on other ATTR treatments
New York Heart Association (NYHA) classification will be compared in patients prescribed eplontersen to patients on other ATTR treatments
Time frame: Up to 7 years
Comparison of Familial amyloid polyneuropathy (FAP) (Coutinho) staging in patients prescribed eplontersen to patients on other ATTR treatments
FAP staging: Stage 0: No symptoms; Stage I: Unimpaired ambulation; mostly mild sensory, motor and autonomic neuropathy in the lower limbs; Stage II: Assistance with ambulation required, mostly moderate impairment progression to the lower limbs, upper limbs, and trunk; Stage III: Wheelchair-bound or bedridden; severe sensory, motor, and autonomic involvement of all limbs.
Time frame: Up to 7 years
Comparison of Left Ventricular Ejection Fraction in patients prescribed eplontersen to patients on other ATTR treatments
Left Ventricular Ejection Fraction will be compared in patients prescribed eplontersen to patients on other ATTR treatments
Time frame: Up to 7 years
Comparison of Charlson comorbidity index (CCI) and CCI components in patients prescribed eplontersen to patients on other ATTR treatments
Charlson comorbidity index (CCI) and CCI components will be compared in patients prescribed eplontersen to patients on other ATTR treatments
Time frame: Up to 7 years
Comparison of other comorbidities of interest in patients prescribed eplontersen to patients on other ATTR treatments
The following outcomes will be compared between patients treated with eplontersen and patients on other ATTR treatments: * Percentage of patients with depression * Percentage of patients with fibromyalgia * Percentage of patients with paraproteinemia
Time frame: Up to 7 years
Comparison of healthcare resource utilization in patients prescribed eplontersen to patients on other ATTR treatments
The following outcomes will be compared between patients treated with eplontersen and patients on other ATTR treatments: * Number of emergency department visits * Number of outpatient visits * Inpatient care/hospitalization general ward (non-intensive): number of inpatient stays, number of bed days * Inpatient care/hospitalization intensive ward: number of inpatient stays, number of bed days
Time frame: Up to 7 years
Comparison of mortality in patients prescribed eplontersen to patients on other ATTR treatments
Mortality will be compared in patients prescribed eplontersen to patients on other ATTR treatments
Time frame: Up to 7 years
Risk factors for worsening ATTR progression
Factors associated with changes in clinical manifestations of ATTR amyloidosis, NYHA classification, NAC ATTR staging or Mayo staging, FAP (Coutinho) staging, PND score, LVEF, CCI and CCI components, and other comorbidities of interest will be identified.
Time frame: up to 7 years
Healthcare costs in patients with ATTR amyloidosis
Average annual costs will be calculated based on available data in the different countries.
Time frame: Up to 7 years
Serious adverse events in patients treated with ATTR amyloidosis treatments
Serious adverse events in patients treated with ATTR amyloidosis treatments will be measured
Time frame: Up to 7 years
Plan to share: Yes — Plan to share only the redacted CSR synopsis
Supporting information: Clinical study report
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Data sharing details ↗ · vivli.org
Started Jun 2024 (actual). Primary completion is estimated for Dec 2031, 90 months after the start.
Of 25 observational studies under Amyloidosis, Hereditary, Transthyretin-Related, half reached primary completion within 93 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 97. This study's planned 90 months is close to that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Amyloidosis, Hereditary, Transthyretin-Related →